Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from EKF Diagnostics Holdings ( (GB:EKF) ).
EKF Diagnostics Holdings announced a trading update for FY 2024, highlighting a strategic shift towards higher-margin product ranges and core operations, resulting in expected full-year revenues of £50.2 million, down from £52.6 million in FY 2023. However, gross margins improved, and adjusted EBITDA is anticipated to be not less than £11.0 million, up from £10.4 million the previous year, driven by reduced administration expenses. The company repaid all bank borrowings, ending the year with £14.3 million in cash, and is considering various options for utilizing this cash in 2025 to enhance shareholder value.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is a global diagnostics business listed on AIM, focusing on Point-of-Care analyzers in hematology and diabetes, and life sciences services which offer the manufacture of enzymes and custom products for diagnostics, food, and industrial applications. With headquarters in Penarth, UK, it operates five manufacturing sites across the US and Germany and sells its products in over 120 countries worldwide.
YTD Price Performance: -2.78%
Average Trading Volume: 333,989
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £120.2M
For a thorough assessment of EKF stock, go to TipRanks’ Stock Analysis page.
